mouse monoclonal cd19 antibody  (Novus Biologicals)

Journal: Frontiers in Immunology

Article Title: CD19 + B cell depletion: a novel strategy to alleviate ischemic stroke damage

doi: 10.3389/fimmu.2025.1528471

Figure Lengend Snippet: Clinical and laboratory characteristics of the stroke patients.

Article Snippet: As shown in , mice were randomly assigned to receive either monoclonal rat anti-mouse CD19 antibody (1D3, Bio X Cell) (10 mg/kg) or Isotype control antibody (2A3, Bio X Cell) (10 mg/kg) by intraperitoneal injection 3 days in advance, creating the CD19 Ab-treatment group and the Iso Ab-treatment group, respectively.

Techniques:

Journal: Frontiers in Immunology

Article Title: CD19 + B cell depletion: a novel strategy to alleviate ischemic stroke damage

doi: 10.3389/fimmu.2025.1528471

Figure Lengend Snippet: Injection of aCD19 Ab reduced meningeal local and systemic inflammatory response. (a) The IF co-staining results of LYVE-1 and CD31 at 20 times magnification (Scale bar=100 μm) (data were presented as mean ± SD, n=3, *** p < 0.001). (b) (i) The IF staining results of CD19 in meninges tissue at 60 times magnification (Scale bar=20 μm) (data were presented as mean ± SD, n=3, *** p < 0.001). ii. The IF staining results of MPO in meninges tissue at 60 times magnification (Scale bar=20 μm) (n=3, * p < 0.05). (c) Representative IHC staining of B cells, Neutrophils and T cells in the infarct area at 60 times magnification (Scale bar=20 μm) and their statistical analysis of the ratio of the positive cells to the total cells number (data were presented as mean ± SD, n=3, *** p < 0.001 and ** p < 0.01). (d) The Flow Cytometry results of immune cells in peripheral blood of MCAO/R mouse. (i) CD4 + T cells. ii. CD8 + T cells. iii. Neutrophils (data were presented as mean ± SD, n=3, ** p < 0.01). (e) Expression of the inflammatory cytokines in cerebral parenchyma (data were presented as mean ± SD, n=3).

Article Snippet: As shown in , mice were randomly assigned to receive either monoclonal rat anti-mouse CD19 antibody (1D3, Bio X Cell) (10 mg/kg) or Isotype control antibody (2A3, Bio X Cell) (10 mg/kg) by intraperitoneal injection 3 days in advance, creating the CD19 Ab-treatment group and the Iso Ab-treatment group, respectively.

Techniques: Injection, Staining, Immunohistochemistry, Flow Cytometry, Expressing

Journal: Frontiers in Immunology

Article Title: CD19 + B cell depletion: a novel strategy to alleviate ischemic stroke damage

doi: 10.3389/fimmu.2025.1528471

Figure Lengend Snippet: The status of meningeal immune cell infiltration and peripheral immune cell changes in stroke patients. (a) The IF co-staining results of LYVE-1 (Red) and MPO (Green) in meningeal tissue at 60 times magnification (Scale bar=20 μm). (b) The IF co-staining results of LYVE-1 (Red) and CD19 (Green) in meningeal tissue at 60 times magnification (Scale bar=20 μm). (c) Comparison of the ratio of the CD19 and MPO positive cells to the total cells number in meningeal(data were presented as mean ± SD, n=3).

Article Snippet: As shown in , mice were randomly assigned to receive either monoclonal rat anti-mouse CD19 antibody (1D3, Bio X Cell) (10 mg/kg) or Isotype control antibody (2A3, Bio X Cell) (10 mg/kg) by intraperitoneal injection 3 days in advance, creating the CD19 Ab-treatment group and the Iso Ab-treatment group, respectively.

Techniques: Staining, Comparison